SECTORS TODAY
Tech XLK -4.89%
Financials XLF -0.76%
Healthcare XLV +0.45%
Energy XLE +1.91%
Industrials XLI -1.60%
Cons. Disc. XLY -0.71%
Cons. Staples XLP +1.41%
Utilities XLU +0.67%
Materials XLB +0.40%
Real Estate XLRE +0.26%
Comm. Svcs XLC -1.29%

Earnings release · V

Visa Reports Fiscal Fourth Quarter and Full-Year 2026 Results

Visa Inc. · Filed · SEC Form 8-K, Item 2.02

Visa company page Original on SEC.gov ↗

Revenue $12.1 +13% vs a year ago
EPS $3.19 +18% vs a year ago
Guidance issuedoutlook statement
Automated extract. The items below were picked out of the company's press release by software and may be wrong or incomplete. Please read the original before relying on any figure. Not investment advice.

Why it matters

Revenue increased 13% year on year to $12.1, and EPS climbed 18% to $3.19. Growth in both sales and earnings is the combination investors usually look for first. The company issued new guidance, which gives a first marker for expectations in the periods ahead.

Written automatically by Stocknote's note engine from the figures on this page and the company's previous release. Every number in this note is checked against those figures. Not investment advice.

What the company states

Revenue

$12.1 +13% vs a year ago

…Net revenue of $12.1B, an increase of 13% on a nominal and constant-dollar basis.…
EPS

$3.19 +18% vs a year ago

…GAAP net income in the fiscal fourth quarter was $6.0 billion or $3.19 per share, an increase of 18% and 22%, respectively, over prior year’s r…
Guidance

Guidance issued

…ts, strategies, business growth, anticipated timing and benefits of our acquisitions, and financial outlook.…

Read the original press release on SEC.gov ↗ Filing index ↗

Trend: last 1 reports

All releases →

Revenue growth (YoY)

EPS growth (YoY)

Our research on V

Company page →
Disclaimer: This page is generated automatically from public SEC filings for information only. Stocknote does not edit the company's release and does not guarantee the accuracy of the extracted items. Read the full disclaimer here.

Get new research in your inbox

Forensic equity research on US stocks. No spam, unsubscribe anytime.